Satellos Bioscience Inc.
MSCLF
$0.49
-$0.05-9.79%
OTC PK
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -10.41% | 14.95% | |||
| Gross Profit | 10.41% | -14.95% | |||
| SG&A Expenses | -0.26% | 18.82% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.73% | 16.08% | |||
| Operating Income | 1.73% | -16.08% | |||
| Income Before Tax | 8.26% | -39.34% | |||
| Income Tax Expenses | -49.21% | -- | |||
| Earnings from Continuing Operations | 8.68% | -40.78% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 8.68% | -40.78% | |||
| EBIT | 1.73% | -16.08% | |||
| EBITDA | 1.71% | -16.24% | |||
| EPS Basic | 11.35% | -2.21% | |||
| Normalized Basic EPS | 10.92% | -1.33% | |||
| EPS Diluted | 11.35% | -2.21% | |||
| Normalized Diluted EPS | 10.92% | -1.33% | |||
| Average Basic Shares Outstanding | 3.26% | 37.62% | |||
| Average Diluted Shares Outstanding | 3.26% | 37.62% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||